PharmaShots Weekly Snapshots (January 22 – January 25, 2024)

Share this

PharmaShots Weekly Snapshots (January 22 – January 25, 2024)

This week PharmaShots’ news was all about the updates on Regulatory, Clinical Trials,Pharma, Animal Health & MedTech. Check out our full report below:


The US FDA Grants Full Approval to Johnson & Johnson’s Balversa for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma (UC)

Read More: Johnson & Johnson                                                  

Health Canada Approves Galderma’s Restylane SHAYPE for Chin Augmentation

Read More: Galderma                                                      

The US FDA Clears Harbour BioMed’s IND Application of HBM9027 for Solid Tumors

Read More: Harbour BioMed                                                   

The US FDA Issues Complete Response Letter to Theratechnologies’ sBLA of Tesamorelin for Abdominal Fat Reduction in HIV and Lipodystrophy Patients

Read More: Theratechnologies                                                     

The USPTO Grants Patent to RedHill’s Talicia for H. Pylori Infections

Read More: RedHill                                                   


BMS Highlights Results from the P-III (CheckMate -8HW) Study of Opdivo (nivolumab) + Yervoy (ipilimumab) for Metastatic Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium 2024

Read More: BMS                                                                  

AstraZeneca Highlights the P-III Results for the Combination of Imfinzi, TACE, and Bevacizumab to Treat Hepatocellular Carcinoma (HCC)

Read More: AstraZeneca                                                     

BMS Highlights 4-Year Follow-Up Data from P-III Evaluation of Opdivo with Cabometyx to Treat Advanced Renal Cell Carcinoma (RCC) 

Read More: BMS                                                        

BioNTech and DualityBio Initiate the P-III Evaluation of BNT323/DB-1303 in Metastatic Breast Cancer 

Read More: BioNTech & DualityBio                                                        

Ionis Highlights Results from the P-III (OASIS-HAE) Study of Donidalorsen for Treating Hereditary Angioedema

Read More: Ionis                                                        

 Eli Lilly Reports Data from the P-I/II (AK-OTOF-101) Trial of AK-OTOF for Genetic Hearing Loss

Read More: Eli Lilly                                                       

PharmAbcine Initiated P-Ia/b Study by Dosing First Patient with PMC-309 for Treating Advanced or Metastatic Solid Tumors

Read More: PharmAbcine                                                   

Ferring Pharmaceutical Highlights the Updates on its Real-World Evidence Study for Adstiladrin in Bladder Cancer 

Read More: Ferring Pharmaceutical                                                        

Onward Therapeutics Highlights the P-I Trial Updates of OT-A201 for the Treatment of Solid Tumors

Read More: Onward Therapeutics                                                      


Coherus BioSciences Reports the Divestiture of its Ophthalmology Franchise to Sandoz for $170M Up Front 

Read More: Coherus BioSciences & Sandoz                                 

Arcutis Introduces Zoryve (roflumilast) Topical Foam, 0.3%, for Treating Seborrheic Dermatitis in the US

Read More: Arcutis                                                                       

GenEdit and Genentech Collaborate to Discover and Develop Novel Nanoparticles for Autoimmune Diseases

Read More: GenEdit & Genentech                                                      

EraCal Therapeutics Signs a Collaboration and License Agreement with Novo Nordisk to Develop and Commercialize its Small Molecule Program 

Read More: EraCal Therapeutics & Novo Nordisk                                      

Elegen and GSK Sign a Collaboration Agreement to Develop Elegen’s Cell-Free DNA Production Technology

Read More: Elegen & GSK                                                                              


Veterinary Pharmaceutical Solutions to Acquire Diamond Animal Health

Read More: Veterinary Pharmaceutical Solutions & Diamond Animal Health           


Pi-Cardia’s ShortCut has been Granted with Breakthrough Device Designation from the US FDA

Read More: Pi-Cardia                                                      

Bionano Introduces Stratys System for High Throughput Optical Genome Mapping (OGM)

Read More: Bionano                                                      

AbSolutions Med’s Obtains US FDA’s Breakthrough Device Designation for Rebuild Bioabsorbable Abdominal Wall Closure Device for Incisional Hernia

Read More: AbSolutions Med                                                                          


For an Aggregate of $2.2B, Sanofi Acquires Inhibrx Thereby Adding INBRX-101 for Alpha-1 Antitrypsin Deficiency (AATD) to its Pipeline

Read More: Sanofi & Inhibrx                                                    

Related Post:- PharmaShots Weekly Snapshots (January 15 – January 19, 2024)

Shivani Chandra

Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions